About the job
Attention recruitment agencies: All agency inquiries are vetted through 4DMT’s internal Talent Acquisition team. No unsolicited resumes will be accepted. The 4DMT Talent Acquisition team must expressly engage agencies on any requisition. Agencies contacting hiring managers directly will not be tolerated, and doing so may impact your ability to work with 4DMT in the future.
4D Molecular Therapeutics (4DMT) is a pioneering biotechnology company dedicated to developing transformative, durable therapeutics aimed at specific diseases, with the potential to revolutionize treatment protocols and offer unmatched benefits to patients. Our flagship product candidate, 4D-150, is engineered to serve as a cornerstone therapy for the management of blinding retinal vascular diseases, enabling multi-year sustained delivery of anti-VEGF agents (aflibercept and anti-VEGF-C) through a single, safe intravitreal injection, significantly alleviating the treatment burden associated with current bolus injections. Currently in Phase 3 development for wet age-related macular degeneration, our lead indication, 4D-150 also addresses diabetic macular edema. Additionally, our second product candidate, 4D-710, represents the first successful delivery and expression of the CFTR transgene in the lungs of cystic fibrosis patients via aerosol delivery.
GENERAL SUMMARY
The Vice President of Supply Chain will spearhead the comprehensive strategy, execution, and governance of global supply operations throughout all development phases. This position is critical in ensuring a continuous, compliant, and cost-effective supply of investigational and commercial products, comparators, ancillaries, and open-label therapies necessary for global clinical trials and commercial launches.
This leader will be responsible for establishing and scaling a world-class supply organization, collaborating closely with Clinical Operations, CMC, Regulatory, Quality, and external vendors, while providing senior oversight of supply risk, forecasting, and readiness to support pivotal development and regulatory milestones.

